The purpose of this study is to explore the association between serum growth differentiation factor 15 (GDF15) and metabolic syndrome (MS), as well as its components in patients with Type 2 diabetes mellitus (T2DM). This evidence concerns the gene GDF15 and myeloid sarcoma.